Amneal Plans Eight More ‘High Value’ Launches

Company Awaits FDA Approval For 91 Products

 
• By Akriti Seth

Based on its “solid track record of filing, getting approval and launching high-value generics,” Amneal not only plans to launch eight new “high value” products over the next year, the company also plans to file for another 20-25 generics. Amneal has 91 products in the pipeline awaiting FDA approval and 132 products actively in development, mainly in non-oral solid dosage forms.

Wooden blocks
Amneal says it will meet its targets despite COVID-19 related headwinds • Source: Shutterstock

Working to strengthen its generics segment, Amneal Pharmaceuticals plans to launch a further eight new “high value” generics within the next year. “So far,” commented Chirag Patel, co-CEO, president and director of Amneal, “we have launched seven of our target of launching 15 new complex generic products by 2021.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business